Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd. is a global biopharmaceutical firm dedicated to discovering, acquiring, advancing, and commercializing medical therapies for individuals suffering from severe illnesses where current treatment options are insufficient. Its pipeline of potential treatments includes ARCALYST, an interleukin-1alpha and interleukin-1beta inhibitor, aimed at addressing recurrent pericarditis, an inflammatory heart condition. Also in development is Mavrilimumab, a monoclonal antibody inhibitor that has successfully concluded Phase II clinical trials for managing giant cell arteritis. Additionally, Vixarelimab, another monoclonal antibody, is currently undergoing Phase 2a clinical trials as a potential therapy for prurigo nodularis, a persistent inflammatory skin disorder. The company's pipeline further includes KPL-404, a monoclonal antibody engineered to inhibit the CD40-CD154 interaction, which plays a crucial role in T-cell co-stimulation, B-cell development, immunoglobulin class switching, and the body's type 1 immune response. Established in 2015, Kiniksa Pharmaceuticals, Ltd. operates from its headquarters in Hamilton, Bermuda.